MYBPH Inhibitors
MYBPH (Myosin-binding protein H) inhibitors represent a class of compounds that exert their biochemical effects through the inhibition of the MYBPH protein. MYBPH is a crucial regulatory protein involved in the function of striated muscle, particularly in cardiac and skeletal muscle tissues. This protein plays a pivotal role in the modulation of muscle contraction and relaxation by binding to myosin, a motor protein responsible for muscle contraction. By binding to myosin, MYBPH fine-tunes the mechanical properties of muscle contraction, contributing to the overall control of muscle function.
Inhibitors of MYBPH are designed to interfere with the interaction between MYBPH and myosin, disrupting the normal regulatory processes that govern muscle contraction. These compounds may act by binding to specific regions of MYBPH or altering its conformation, ultimately reducing its ability to bind to myosin effectively. As a consequence, MYBPH inhibitors can lead to alterations in muscle contractility and relaxation, potentially affecting muscle performance.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin inhibits MYBPH by binding to the ATP-binding site, preventing the myosin ATPase activity and, consequently, muscle contraction. It is commonly used in research to study myosin function and actin-myosin interactions. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is a selective inhibitor of MYBPH by targeting myosin light chain kinase (MLCK). It disrupts the phosphorylation of the myosin light chain, leading to decreased myosin-actin interaction and muscle contraction. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits MYBPH by blocking Rho-associated protein kinase (ROCK), which indirectly regulates myosin phosphorylation. It reduces smooth muscle contraction and is used in various biological studies. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
CK-666 is an inhibitor of the actin-binding protein Arp2/3 complex, indirectly affecting MYBPH by disrupting actin polymerization and organization. It impairs actin-myosin interactions in cells. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
SMIFH2 inhibits MYBPH by targeting the Arp2/3 complex, disrupting actin filament branching and organization. This leads to impaired cellular motility and contraction. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts MYBPH function by binding to actin filaments, preventing their polymerization and depolymerization, and consequently inhibiting muscle contraction and cell motility. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Latrunculin A inhibits MYBPH by sequestering G-actin monomers, preventing their polymerization into F-actin. This disrupts the actin cytoskeleton and impairs muscle contractility. | ||||||
CK-869 | 388592-44-7 | sc-507274 | 5 mg | $163.00 | ||
CK-689 is an inhibitor of MYBPH that interferes with the actin-myosin interaction by binding to the myosin ATP-binding site. This results in reduced ATP hydrolysis and muscle relaxation. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is a potent inhibitor of protein phosphatases, including myosin phosphatase, which dephosphorylates the myosin light chain. Inhibition leads to sustained myosin activation and muscle contraction. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide disrupts MYBPH function by stabilizing F-actin filaments, making them resistant to depolymerization. This results in increased actin-myosin interaction and sustained muscle contraction. | ||||||